Robert S. DiPaola

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810”.

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Journal of Clinical Oncology(2024)10.1200/jco.23.01544

N/A

0.930DataRank · unranked

19 citations

Se Eun Kim, Wayne Harris, Sumanta K. Pal, Michael R. Pins, Jill Kolesar +13 more

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

Cancer Medicine(2021)10.1002/cam4.4140

N/A

0.315DataRank · unranked

5 citations

Hannah Fullington, David E. Gerber, I. Alex Bowman, Mäneka Puligandla, Janice P. Dutcher +3 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7018

N/A

0.203DataRank · unranked

2 citations

Yael Flamand, Naomi B. Haas, Anne O’Neill, Robert S. DiPaola, Pearl Subramanian +6 more

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

Annals of Oncology(2021)10.1016/j.annonc.2021.06.003

N/A

0DataRank · unranked

77 citations

Hsin-Chieh Huang, V. Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den +11 more

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0025

N/A

0DataRank · unranked

46 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo +5 more

Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.342

N/A

0DataRank · unranked

0 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert Guy Uzzo +5 more

Collaborative team dynamics and scholarly outcomes of multidisciplinary research teams: A mixed-methods approach

Journal of Clinical and Translational Science(2023)10.1017/cts.2023.9

N/A

0DataRank · unranked

16 citations

Philip A. Kern, Robert L. Kegebein, Chang Liu, Joel Thompson, Thomas H. Kelly +4 more

Optimizing team science in an academic medical center: A qualitative examination of investigator perspectives

Journal of Clinical and Translational Science(2023)10.1017/cts.2023.3

N/A

0DataRank · unranked

8 citations

Janet K. Otachi, Emily Slade, Philip A. Kern, Victoria King, Thomas H. Kelly +2 more

Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.123

N/A

0DataRank · unranked

1 citations

Yu‐Hui Chen, Christopher Sweeney, David F. Jarrard, Elizabeth R. Plimack, Benjamin A. Gartrell +7 more

Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5014

N/A

0DataRank · unranked

0 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynne I. Wagner +4 more

Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)

European Urology Oncology(2024)10.1016/j.euo.2024.04.010

N/A

0DataRank · unranked

8 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynn I. Wagner +4 more

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Annals of Oncology(2025)10.1016/j.annonc.2025.08.004

N/A

0DataRank · unranked

7 citations

Y. Chen, David F. Jarrard, Jorge A. García, R. Dreicer, Guoqiang Liu +12 more

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2019.6496

N/A

0DataRank · unranked

75 citations

Christopher J. Sweeney, Nima Almassi, Chad A. Reichard, C.A. Reddy, Hong Li +9 more

Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

European Urology Oncology(2025)10.1016/j.euo.2025.04.003

N/A

0DataRank · unranked

1 citations

Xiangying Chu, Charles J. Ryan, Arjun Gupta, Christopher J. Sweeney, David F. Jarrard +10 more

Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)

The Prostate(2020)10.1002/pros.24074

N/A

0DataRank · unranked

21 citations

Victoria X. Wang, Anis Hamid, Gabriella Santone, Charles G. Drake, Michael A. Carducci +4 more

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.162

N/A

0DataRank · unranked

18 citations

Victoria Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den, Gerhardt Attard +10 more

Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.171

N/A

0DataRank · unranked

1 citations

Victoria Wang, Hidemi S. Yamamoto, Anis Hamid, Charles G. Drake, Michael A. Carducci +4 more